You just read:

Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer

News provided by

Trovagene, Inc.

Oct 03, 2018, 08:30 ET